NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

COMPARATIVE EFFICACY OF PARIET (RABEPRAZOLE): LESSONS FROM CLAIMS DATA.

Rocchi A, Lelorier J, Glass J; Health Technology Assessment International. Meeting (3rd : 2006 : Adelaide, S. Aust.).

Handb Health Technol Assess. 2006; 3: 199.

Axia Research, Hamilton; Hotel Dieu, Montreal; Janssen Ortho, Toronto; Canada

Background: Pariet (rabeprazole) was introduced at a substantial price discount to existing, branded proton pump inhibitors (PPIs) in Canada. However, there is a perception of comparative reduced efficacy with Pariet, in part because Pariet is generally dosed at two tablets daily, compared to one unit daily for other PPIs. The objective was to conduct individual claims data descriptive analyses to identify differences in patterns of use indicative of reduced efficacy or selection of patients. Methods: Individual claims data were obtained for Ontario, Canada. PPI claims were followed backward in time to determine if the patient had received a different PPI, an H2 antagonist or neither therapy previously (minimum time period, twelve months). This could suggest selection bias for na patients versus treatment-experienced patients. PPI claims were followed forward in time to determine if there were subsequent claims for a different PPI, an H2 antagonist, or neither. This proxy measure was interpreted as a lack of efficacy requiring therapy switches. Results: Pariet users were equally likely as other PPI users to have had no claims for another PPI or H2 in the previous twelve months (74% PPI market overall, 70% Pariet). The proportion of patients who subsequently switched therapy increased as the duration of follow-up increased. Overall, Pariet users were most likely to have no subsequent claims for another PPI or an H2 antagonist compared to other PPIs (59% overall market, 71% Pariet users). Conclusion: Claims data from Ontario do not support that Pariet has different efficacy from other PPIs or is used differently.

Publication Types:
  • Meeting Abstracts
Keywords:
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Canada
  • Humans
  • Ontario
  • rabeprazole
  • hsrmtgs
UI: 103724965

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov